Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
wXELIRI in advanced colorectal cancer
NCT01322152Phase 2Completed
- Sponsor
- Fudan University
- Start
- Mar 2011
- Primary completion
- May 2013
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and capecitabine in colorectal cancer (CRC), sponsored by Fudan University. Primary endpoint: Rate of Diarrhea at 8 weeks. Started Mar 2011; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabcapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01322152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01322152.